In 2018, a Bioinformatics study has identified miR-199a and miR-142–3-P as crucial biomarkers in MS due to targeting the pivotal susceptibility genes, in particular KRAS and IL7R. They also examined IL7R expression in a small population of MS and control patients (15 MS, 14 controls) and reported an increased expression of this gene, which contradicts our study33. This evidence concerns the gene KRAS and myeloid sarcoma.